Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...

Although significant progress has been made in the treatment and management of patients with FL, several challenges remain, including the need to develop better prognostic models and markers for ...

In December 2025, Celcuity Inc. reported updated Phase 3 VIKTORIA-1 trial results at the San Antonio Breast Cancer Symposium, showing gedatolisib-based regimens improved progression-free survival and ...

Serial cell-free DNA (cfDNA) sampling in advanced pancreatic ductal adenocarcinoma (PDAC) patients may predict therapeutic outcome. This is an ASCO Meeting Abstract from the 2021 Gastrointestinal ...

First-in-human trial of candidate from the next-generation ATTC platform —— Simultaneous China and global clinical development strategy to ...

A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.

Interrupting one function of a protein that plays a key role in cell signaling could enable the development of new cancer ...